CTLA4 degradation is delayed in the absence of USP8. (A–F) Representative western blots and associated quantifications of Cycloheximide (CHX; 100 µg/ml) chase experiments in HeLa S3 Flp-In CTLA4-HA (A, C, and E) and A2058 (B, D, and F) cells following treatment with non-targeting (NT1), AMSH, USP8, or HRS siRNA for 72 h. The half-life of CTLA4 was estimated using an exponential decay model. Error bars show SD from three independent experiments. Source data are available for this figure: SourceData F3.